Biosimilar Specialist Henlius Takes Off. Now Comes the Hard Part
Fosun Pharma-backed company posts huge revenue jump in the second half of last year, as it boosts production and signs more global licensing deals to stay ahead of competition Key…
RELATED ARTICLES
-
As its stock gets set for upgrade, Boan Biotech still faces two big risks
6955.HK
-
Henlius finds elixir in first profits, scraps A-share IPO
2696.HK
-
FAST NEWS: Henlius expects first-ever annual profit on strong drug sales
2696.HK
-
FAST NEWS: Henlius swings to the black on strong sales growth
2696.HK
-
Debt pressures cast cloud over Fosun Pharma results
2196.HK 600196.SHG
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
Discover hidden China stock gems in our weekly newsletter